Analyst consensus rating
RenovoRx Analyst Rating: none
Direct answer
RenovoRx's consensus rating is none.
4 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $7.13.
Forecast evidence checked October 19, 2026.
Get free RenovoRx email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $1.14
- Average price target
- $7.13
- High price target
- $14.50
- Low price target
- $3.00
- Low target gap
- +163.2%
- Target upside
- +525%
- High target gap
- +1,171.9%
- Target range width
- 1,008.8%
- Consensus rating
- none
- Analysts
- 4
- Evidence date
- October 19, 2026
- Valid through
- October 26, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for RenovoRx?
RenovoRx has a verified none consensus. The same dataset has an average price target of $7.13.
How far are RenovoRx's low and high targets from the recorded price?
The low target implies +163.2%, while the high target implies +1,171.9%.
How many analysts are included in RenovoRx's consensus?
The verified consensus includes 4 analysts.
How is RenovoRx's target upside or downside calculated?
The average target of $7.13 is divided by the recorded price of $1.14, then one is subtracted to produce +525%. This does not guarantee a future return.
When was RenovoRx's analyst forecast verified?
The data was verified on 2026-10-19. The dataset is valid through 2026-10-26.